Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited announced that its CEO, Silviu Itescu, will deliver a featured presentation at the ISCT North America Regional Virtual Town Hall, highlighting RYONCIL as the first FDA-approved mesenchymal stromal cell therapy. This event underscores Mesoblast’s leadership in the cellular medicine industry and its commitment to expanding its innovative therapies to treat various inflammatory diseases, potentially enhancing its market position and stakeholder value.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. The company specializes in mesenchymal lineage cell therapy technology, which releases anti-inflammatory factors to modulate the immune system. Mesoblast’s flagship product, RYONCIL, is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease in pediatric patients. The company is expanding its product pipeline to address other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
YTD Price Performance: 21.82%
Average Trading Volume: 281,886
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.6B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com